Uterine leiomyomas or uterine fibroids are the most common gynaecological tumours and occur in about 20-50% of women around the world. Ultrasonography (USG) is the first-line imaging examination in suspected fibroids and shows high sensitivity and specificity in diagnosing this condition. Ultrasound scans can be performed transvaginally (transvaginal scan – TVS) or transabdominally (transabdominal scan – TAS); both scans have advantages and limitations, but, in general, transvaginal sonography is superior to transabdominal sonography in most cases of pelvic pathology. Whether a leiomyoma is symptomatic or not depends primarily on its size and location. During ultrasound examination, leiomyomas usually appear as well-defined, solid, concentric, hypoechoic masses that cause a variable amount of acoustic shadowing. During the examination of leiomyomas differential diagnosis is important. Some of the most common misdiagnosed pathologies are adenomyosis, solid tumours of adnexa, and endometrial polyps.
The following table describes the differentiating features between fibroid and adenomyosis.
Feature Typical fibroid Adenomyosis
Serosal contour of uterus Lobulated or regular Often globally enlarged uterus
Definition of lesion Well‐defined Ill‐defined in diffuse adenomyosis (adenomyoma may be well‐defined)
Symmetry of uterine walls Asymmetrical in presence of well‐defined lesion(s) Myometrial anteroposterior asymmetry Lesion
Outline Well‐defined Ill‐defined
Shape Round, oval, lobulated Ill‐defined
Contour Smooth Irregular or ill‐defined
Rim Hypo‐ or hyperechogenic No rim
Shadowing Edge shadows, internal shadows (often fan‐shaped shadowing)
Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2394 Market Potential and PitfallsUterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race.
The U.S. uterine fibroid market is anticipated to touch high growth figures in the long run mainly due to the surging prevalence of uterine fibroids and the rising number of hysterectomy surgeries every year.
Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth.
Such surgeries have reduced the chances of infection, reduced the hospital stay, and, lowered the recovery time, thereby contributing to the growth.
This has resulted in limited treatment options for uterine fibroids.
Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/2394Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound.
The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities.
The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.Segmentation:The U.S.
Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.By type, the Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others.
Uterine Fibroid market includes Magnetic Resonance Guided Focused Ultrasound, Uterine Fibroid Embolization, Endometrial Ablation, Myolysis, Hysterectomy, and Myomectomy.Regional InsightsThe U.S. uterine fibroid market is expanding at a steady pace with a CAGR of 3.24% by the end of 2022.
